Chargement en cours...
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
BACKGROUND: Fluvoxamine therapy is used for treatment of patients with depressive disorder, but it is often ineffective, and some patients suffer from dose-dependent undesirable side effects such as vertigo, headache, indigestion, xerostomia, increased anxiety, etc. CYP2D6 is involved in the biotran...
Enregistré dans:
| Publié dans: | Pharmgenomics Pers Med |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6029588/ https://ncbi.nlm.nih.gov/pubmed/29988737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S160763 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|